Mutations in the RET proto-oncogene can lead to the development of cancers such as medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2), and sporadic pheochromocytomas. These mutations can be activating, leading to uncontrolled cell proliferation, or inactivating, resulting in loss of normal cellular functions.
